View Older Stories View More Recent Stories
-
BMO Capital Downgrades Omnicom Group (OMC) to Market Perform
-
Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
-
Amgen (AMGN): BMO Sees Inceased Competitive Risk to KYPROLIS
-
Notable Analyst Rating Changes 2/10: (STJ) (C) (TE) Upgraded; (RIG) (BPZ) (GPS) Downgraded
-
BMO Capital Upgrades Harmony Gold (HMY) to Market Perform
-
BMO Capital Upgrades Hasbro (HAS) to Outperform
-
BMO Capital Starts Patriot National (PN) at Outperform
-
BMO Capital Reiterates Bullish Stance on Regulus Therapeutics (RGLS) as Incremental Efficacy of RG101 Could Support New Option in HCV
-
Notable Analyst Rating Changes 2/9: (MOS) (PFE) (AMC) Upgraded; (CENX) (ANF) (RF) Downgraded
-
Tahoe Resources (TAHO) to Buy Rio Alto Mining (RIOM) for About C$4/Share
-
BMO Capital Starts Post Holdings (POST) at Outperform
-
BMO Capital Upgrades Pfizer (PFE) to Outperform Amid Hospira Takeover
-
Twitter (TWTR) PT Bumped to $47 at BMO Capital on on Q4 Monetization
-
BMO Keeps ISIS Pharma (ISIS) at 'Outperform' Following ISIS-BIIB4Rx Milestone
-
Intercept Pharma (ICPT) 1M Stock Offering Prices at $176/Share
-
BMO Capital Downgrades ADP (ADP) to Market Perform
-
Costco Wholesale (COST) PT Lifted to $165 at BMO Capital
-
Intercept Pharmaceuticals Announces Pricing of Public Offering
-
Abbvie (ABBV) PT Cut to $60 at BMO Capital as Cautious Thesis Materializing Faster
-
Auspex Pharmaceuticals (ASPX) PT Boosted to $105 at BMO Capital; Increasing Confidence in SD-809
-
BMO Capital Downgrades Fiserv (FISV) to Market Perform
-
BMO Capital Downgrades Dean Foods (DF) to Market Perform
-
Ziopharm Oncology (ZIOP) Prices 10M COmmon Offering at $8.75/Share
-
Walt Disney (DIS) PT Raised to $115 at BMO Capital
-
Notable Analyst Rating Changes 2/3: (NBL) (LNKD) (SYY) Upgraded; (VR) (FCX) (CNP) Downgaded
-
BMO Capital Upgrades Tenet Healthcare (THC) to Outperform
-
BMO Capital Upgrades Blackhawk Network (HAWK) to Outperform
-
Ziopharm Oncology (ZIOP) to Commence $75M Stock Offering
-
ZIOPHARM Oncology Announces Proposed Public Offering of Common Stock
-
Notable Analyst Rating Changes 2/2: (DMND) (CPLP) (DECK) Upgraded; (GES) (GHL) (ARR) Downgraded
-
BMO Capital Upgrades Rock-Tenn (RKT) to Outperform
-
BMO Capital Upgrades MeadWestvaco (MWV) to Outperform
-
BMO Capital Upgrades Diamond Foods (DMND) to Outperform
-
BMO Capital Downgrades ACE Ltd (ACE) to Market Perform
-
BMO Capital Upgrades QLogic (QLGC) to Outperform
-
BMO Capital Upgrades Boston Scientific (BSX) to Outperform
-
BMO Capital Downgrades General Mills (GIS) to Market Perform
-
Post Holdings (POST) 6.5M Offering Prices at $47.50/Share
-
Vitae Pharmaceuticals Announces Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Follow-on Public Offering of Common Stock
-
Auspex Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
ZIOPHARM (ZIOP) Bullish Stance Reiterated at BMO Capital Following Meeting with Dr. at MD Anderson
-
Apple (AAPL) Target Lifted to $130 at BMO Capital Following Q1 Results
-
Apple (AAPL) Earnings on Deck; Blow-Out Expected But FX Could Crimp Margin Expansion
-
Post Holdings (POST) Announces $240M Common Offering
-
Post Holdings Announces Proposed Common Stock Offering
-
Notable Analyst Rating Changes 1/23: (LNKD) (LULU) (CHK) Upgraded; (X) (DWA) (XOM) Downgraded
-
Box, Inc. (BOX) IPO Opens Up 44%
-
Auspex Pharmaceuticals (ASPX) Prices 4M Common Follo-On at $56.50/Share
-
Auspex Announces Pricing of Follow on Offering
-
Vitae Pharmaceuticals (VTAE) Prices 3M Common Follow-On at $11.90/Share

